Introduction
============

Preoperative chemoradiotherapy (CRT) followed by principle of total mesorectal excision (TME) is now become the standard treatment for clinically staged, locally advanced mid- or low-rectal cancer, i.e. tumor with extension of cT3-T4 and/or the presence of suspected regional metastatic lymph nodes \[[@b1-yujm-2019-00157]\]. Preoperative CRT may facilitate complete radical resection negative surgical resection margin and sphincter preservation with by downsize and/or downstage of primary tumor \[[@b2-yujm-2019-00157]\], and allow an evaluation of chemo- or radio-sensitivity of tumor against the given therapeutic regimen \[[@b3-yujm-2019-00157]\]. Furthermore, the degree of response to preoperative CRT is regarded a prognostic indicator of patient outcome, and the patients achieving pathological complete response (pCR) after preoperative CRT have been showed excellent disease-free survival (DFS) \[[@b3-yujm-2019-00157]\]. However, pCR rate has been reported in 8-27% of patients receiving preoperative CRT \[[@b4-yujm-2019-00157]-[@b6-yujm-2019-00157]\], and the majority of patients were not achieved pCR. Therefore, it is great importance to identified prognostic factors of patients with residual rectal cancer after preoperative CRT.

Pathological prognostic factors, such as ypTNM stage, perineural invasion, lymphatic invasion, venous invasion, circumferential resection margin (CRM), and tumor regression grade (TRG), are easily identified but are still important for patient outcome and essential to determining further clinical management of patients \[[@b1-yujm-2019-00157],[@b2-yujm-2019-00157],[@b7-yujm-2019-00157]-[@b9-yujm-2019-00157]\]. Several studies investigated the association between pathological factors and patient outcome in rectal cancer patients treated with preoperative CRT, however, data from the previous studies on the prognostic value of pathological factor are inconsistent \[[@b1-yujm-2019-00157],[@b2-yujm-2019-00157],[@b10-yujm-2019-00157]-[@b12-yujm-2019-00157]\]. Quah et al. \[[@b2-yujm-2019-00157]\] demonstrated that "pathologic stage (ypTN stage)" was the most precise prognostic predictor. On the other hand, Gosens et al. \[[@b11-yujm-2019-00157]\] reported that CRM positivity and pathologic lymph node status were most significant factors and their combination might give stronger evidence for patient outcome than classic ypTNM stage. In addition, Huebner et al. \[[@b12-yujm-2019-00157]\] showed that TRG and pathologic lymph node status were relevant prognostic predictors. However, data from other studies on the prognostic value of TRG in rectal cancer patients received preoperative CRT are inconsistent \[[@b2-yujm-2019-00157],[@b9-yujm-2019-00157],[@b12-yujm-2019-00157]-[@b14-yujm-2019-00157]\]. Several factors could be responsible for these discrepancies, including inter-observer variation and different methods of quantifying for tumor regression. Unfortunately, most studies evaluated the prognostic significance of pathological factors in rectal cancer patients treated with preoperative CRT without consideration of pCR. Because patients achieved pCR have all favorable histoprognostic status, including absence of lymphatic invasion, perineural invasion, and venous invasion, negative CRM, ypT0N0 (by seventh Union for International Cancer Control \[UICC\]/American Joint Committee on Cancer \[AJCC\] \[[@b15-yujm-2019-00157]\]), prognostic value of analyzing proven pathological factors could be different in patients with residual disease after preoperative CRT. Therefore, robust pathological prognostic factors of residual disease will also need to be determined.

In this study, we investigated known histoprognostic factors in correlation with patient survival to identify robust prognostic predictors in patients with residual disease after preoperative CRT.

Materials and methods
=====================

1. Patient population
---------------------

After the approval of the Institutional Review Boards of Kyungpook National University Medical Center, medical records of 146 patients with rectal cancer who underwent preoperative CRT followed by TME at Kyungpook National University Medical Center between January 2006 and December 2011 were first corrected (IRB No: 2014-04-215). Patients with clinical evidence of distant metastases at the time of diagnosis and patients who were reported as pCR were excluded. All patients had a biopsy-proven diagnosis of primary rectal adenocarcinoma and were identified locally advanced tumors (cT3-4 or cN+). Hematoxylin and eosin (H&E)-stained slides and formalin-fixed, paraffin-embedded (FFPE) tumor samples from surgically resected specimens for each case were retrospectively retrieved.

2. Preoperative chemoradiotherapy and surgery
---------------------------------------------

All patients received preoperative long-course radiotherapy (45 or 50 Gy over 5 weeks) plus 5-fluorouracil-based concomitant chemotherapy (intravenous bolus or continuous infusion) during radiotherapy. All patients were performed radical resection, according to the principle of TME, between 6 and 8 weeks after the completion of preoperative CRT. The detailed process of preoperative CRT followed by surgical protocol has been previously published \[[@b16-yujm-2019-00157],[@b17-yujm-2019-00157]\].

3. Clinical assessment
----------------------

After surgical resection, patients were followed 3-month intervals for the first 2 postoperative years and 6-month intervals thereafter. The clinical workup included digital rectal examination, serum carcinoembryonic antigen (CEA), colonoscopy, computed tomography (CT) of the abdomen and pelvis or pelvic magnetic resonance imaging, and whole-body positron emission tomography/CT \[[@b16-yujm-2019-00157]\].

The recurrence free survival (RFS) was calculated from the time of surgery until the time of any recurrence of rectal cancer, and the cancer-specific survival (CSS) was calculated from the date of surgery to the date of death caused by rectal cancer or the date of last contact, as applicable.

4. Pathological assessment and tumor regression grade
-----------------------------------------------------

For each surgically resected specimen, tumor size and distance of tumor from distal resection margin were measured at the time of gross examination. The non-peritonealized surface of the surgical specimen was painted with green ink to facilitate recognition of CRM. The specimen was opened along the anterior aspect and fixed in 10% neutral-buffered formalin overnight \[[@b18-yujm-2019-00157]\]. The entire tumor site was serially sectioned and embedded in paraffin, and 4-μm sections were cut and stained with H&E \[[@b1-yujm-2019-00157]\]. All H&E-stained slides were retrospectively reviewed by two pathologists (A.N.S and G.S.Y) blinded to the patients' clinical data and re-evaluated pathological characteristics, as follows: tumor size; presence of lymphatic invasion, perineural invasion, and venous invasion; ypT stage, ypN stage, and ypTNM stage; TRG; and CRM. The tumors stage was determined according to the UICC/AJCC staging manual for colorectal cancer (7th edition) \[[@b15-yujm-2019-00157]\]. Tumor regression of the primary tumor against preoperative CRT was semi-quantitatively assessed using 5-point TRG system as initially described by Rödel et al. \[[@b3-yujm-2019-00157]\], as follows: grade 0, no regression; grade 1, minor regression (\<25% of tumor mass); grade 2, moderate regression (≥25% to 50% of tumor mass); grade 3, good regression (\>50% of tumor mass); and grade 4 (complete remission or pCR). A tumor with acellular mucin pools in whole tissue was considered as pCR and was excluded in the present study. In patients with non-pCR, inter-observer reproducibility for TRG was analyzed. Final consensus in cases showing discrepancies for TRG was reached in common session using the multi-head microscope. The CRM was measured as the shorter distance from the outermost part of the tumor cells to the inked resection margin. To evaluate the exact length, the CRM was measured by a ruler or a microscope graticule, and CRM positivity was defined as ≤1 mm \[[@b19-yujm-2019-00157]\]. If cases with CRMs of 1 to 2 mm were found, additional multiple-level serial and deep sections were examined in these cases to detect CRM positivity by hidden malignancy.

5. *KRAS* and *BRAF* mutation
-----------------------------

Deoxyribonucleic acid (DNA) was extracted from FFPE representative tumor tissues using Maxwell^®^ 16FFPE Tissue LEV DNA Purification kit (Promega, Seoul, Korea) and identified for the presence of mutations in *KRAS* exon 2 (codon 12 and 13) and in *BRAF* V600E using the PNAClamp^TM^KRAS and PNAClamp^TM^BRAF mutation Detection kit (Panagene, Daejeon, Korea) in PNA-mediated real-time polymerase chain reaction (PCR) as described previously \[[@b20-yujm-2019-00157]\]. The efficiency of PCR clamping was calculated by measuring the threshold cycle (Ct) value. Ct values for control and mutation assays were automatically evaluated from SYBR Green amplification plots and delta-Ct values were calculated (control Ct -- sample Ct). A higher delta-Ct value shows that the mutant was efficiently amplified. The cut-off delta-Ct was defined as 2 for *KRAS* and *BRAF* mutation.

6. Statistical analyses
-----------------------

All statistical analyses were performed using IBM SPSS version 19.0 (IBM Co., Armonk, NY, USA). To evaluate the inter-observer agreement for TRG, Cohen's Kappa (*κ*) was used. Significant differences for survival between the two groups were compared using the log-rank test, and survival curves were plotted using the Kapan-Meier method. Multivariate analyses were performed using the Cox proportional hazard regression model to verify the independent prognostic impact for each factor. For multivariate analyses, covariates that were proven to be significant in the univariate analysis were controlled, and any possibility of multicollinearity was excluded from the final model. The hazard ratio (HR) and 95% confidence interval (CI) were assessed for each factor. All tests were two-sided, and statistical significance was considered as *p*\<0.05.

Results
=======

1. Patients' clinicopathologic characteristics
----------------------------------------------

A total of 146 patients with residual disease in the surgically resected rectal cancer after preoperative CRT were analyzed. The baseline characteristics of patients are provided in [Table 1](#t1-yujm-2019-00157){ref-type="table"}. The patient group included 102 (69.9%) male and 44 (30.1%) female with median age of 60.0 years (range, 29-85 years). The majority of patients were identified tumor distance from anal verge of \<5 cm (76.7%) and pretreatment serum CEA level of ≤5 ng/mL (66.9%). At the time of initial diagnosis, 17 (11.6%) patients and 129 (88.4%) had evidence of cTNM stage II and III, respectively.

On gross examination, residual tumor size was ranged from 2.3 to 10.0 cm (median range, 6.0 cm). At the time of surgical resection, 31 tumors (21.2%) were ypTMN stage I, 68 tumors (46.6%) were stage II, and 47 tumors (32.2%) were stage III. When comparing with cTNM stage, 92 (63.0%) patients were experienced downstage after preoperative CRT. For the degree of response to preoperative CRT, TRG 0 was found in 4 of 146 (2.7%) patients, TRG 1 in 21 (14.4%), TRG 2 in 55 (37.7%), and TRG 3 in 66 (45.2%). All cases were independently re-evaluated TRG by two pathologists, and inter-observer agreement was analyzed. When comparing an each TRG, the inter-observer agreement showed a moderate agreement (*κ*=0.508; *p*\<0.001), whereas, when comparing dichotomous groups (TRG 0&1 vs. TRG 2&3), kappa value reached 0.534 (*p*\<0.001). In addition, CRM positivity was observed in 30 of 146 (20.5%) patients. CRM positivity was more commonly identified in adverse ypT category tumors (*p*=0.001), adverse ypTNM stage tumors (*p*=0.002), tumors with lower TRG, and tumors with perineural invasion (*p*=0.058). Of the 146 patients, mutation testing was available for 105 patients (72.4%), 29 (27.6%) and 4 (3.8%) were identified to have *KRAS* mutant and *BRAF* mutant primary tumors, respectively.

2. Prognostic factors and univariate analyses
---------------------------------------------

At the time last analyses (December 2017), the median follow-up time was 77.8 months (range, 3.1-141.7 months), during which 59 patients (40.4%) experienced recurrence and 41 (28.1%) died of rectal cancer. During follow-up period, two patients treated with cetuximab (epidermal growth factor receptor monoclonal antibody) for their metachronous metastases. The actuarial 5-year RFS and 5-year CSS were 62.0% and 76.0%, respectively. In univariate analysis, the following 10 factors were identified as being significantly associated with shorter RFS or/and CSS: larger residual tumor size; higher ypT category, ypN category, and ypTNM stage; non-downstage after preoperative CRT; lower TRG; presence of lymphatic invasion, perineural invasion, and venous invasion; and CRM positivity (all *p*\<0.005, [Table 2](#t2-yujm-2019-00157){ref-type="table"}; [Fig. 1](#f1-yujm-2019-00157){ref-type="fig"}). Unfortunately, *KRAS* mutation-positivity and *BRAF* mutation-positivity were not associated with RFS (*KRAS*, *p*=0.107; *BRAF*, *p*=0.435) and CSS (*KRAS*, *p*=0.122; *BRAF*, *p*=0.186). Then, we performed subgroup analyses according to downstage and lymph node metastasis (LNM) status after preoperative CRT, respectively. As shown [Table 3](#t3-yujm-2019-00157){ref-type="table"}, in patients subgroup showing non-downstage (n=54), more advanced ypT category, lower TRG, presence of lymphatic invasion, perineural invasion, and venous invasion, and CRM positivity ([Figs. 2A](#f2-yujm-2019-00157){ref-type="fig"}, [2B](#f2-yujm-2019-00157){ref-type="fig"}) were related to worse RFS or CSS, and both. In patients subgroup showing downstage (n=92), larger residual tumor size, higher ypT category, and CRM positivity ([Figs. 2C](#f2-yujm-2019-00157){ref-type="fig"}, [2D](#f2-yujm-2019-00157){ref-type="fig"}) were correlated with poorer RFS or/and CSS. On the other hand, in patients without LNM (n=99), larger residual tumor size, higher ypT category, and CRM positivity ([Figs. 2E](#f2-yujm-2019-00157){ref-type="fig"}, [2F](#f2-yujm-2019-00157){ref-type="fig"}) were associated with shorter RFS or CSS, and both ([Table 3](#t3-yujm-2019-00157){ref-type="table"}). In patients with LNM (n=47), more advance ypT category, lower TRG, presence of perineural invasion and venous invasion, and CRM positivity ([Figs. 2G](#f2-yujm-2019-00157){ref-type="fig"}, [2H](#f2-yujm-2019-00157){ref-type="fig"}) correlated with worse RFS or/and CSS ([Table 3](#t3-yujm-2019-00157){ref-type="table"}).

3. Multivariate analyses
------------------------

As shown [Table 4](#t4-yujm-2019-00157){ref-type="table"}, multivariate analyses revealed the following independent unfavorable prognostic factors for RFS: larger residual tumor size (HR=1.753; *p*=0.049), CRM positivity (HR=3.613; *p*\<0.001), and presence of venous invasion (HR=20.425; *p*\<0.001); and for CSS: higher ypTNM stage (HR=3.413; *p*=0.004), larger residual tumor size (HR=2.371; *p*=0.020) presence of perineural invasion (HR=2.634; *p*=0.009), and CRM positivity (HR=4.133; *p*\<0.001).

Then, we also evaluated the independency of prognostic factors within aforementioned subgroups. In patients with non-downstage, for RFS, presence of venous invasion (HR=18.066; *p*\<0.001) and CRM positivity (HR=3.715; *p*=0.004); for CSS, presence of venous invasion (HR=4.072; *p*=0.023), perineural invasion (HR=3.067; *p*=0.023), and CRM positivity (HR=2.666; *p*=0.043) were independent negative prognostic factors, respectively. While, in patients with downstage, for RFS, CRM positivity (HR=2.388; *p*=0.028); for CSS, larger residual tumor size (HR=3.599; *p*=0.028) and CRM positivity (HR=3.829; *p*=0.019) were independent adverse prognostic factors, respectively. Additionally, in patients without lymph node metastasis, for RFS, CRM positivity (HR=2.841; *p*=0.007); for CSS, larger residual tumor size (HR=3.589; *p*=0.028) and CRM (HR=4.257; *p*=0.011) were independent worse prognostic factors, respectively. Whereas, in patients with LNM, for RFS, CRM positivity (HR=3.011; *p*=0.005); for CSS, presence of perineural invasion (HR=2.973; *p*=0.027) and CRM positivity (HR=3.053; *p*=0.018) were independent negative prognostic factors, respectively.

Discussion
==========

Accurate pathological examination of surgical specimens resected from rectal cancer patients treated with preoperative CRT is crucial in determining prognostic factors, such as pCR, that may affect patient outcome and subsequent therapeutic management. However, robust pathological factors of residual disease associated with patient outcome have yet to be fully elucidated. Therefore, analyzing known histoprognostic factors in patients with residual disease allows correlations with patient outcome to be evaluated. In our study, we investigated associations between histoprognostic factors and survival in patients with residual rectal cancer after surgical resection, who had received preoperative CRT. Our results revealed that residual tumor size, ypT category, ypN category, ypTNM stage, downstage, TRG, lymphatic invasion, perineural invasion, venous invasion, and CRM were significantly associated with RFS and/or CSS in patients with residual rectal cancer after preoperative CRT. Of these factors, CRM positivity was identified as an independent prognostic factor associated with poorer outcome with respect to RFS and CSS. Furthermore, CRM positivity was an independent predictor of reduced RFS and CSS, irrespective of subgrouping according to downstage or LNM. These findings are in strong accordance with the results of previous studies of rectal cancer patients treated with preoperative CRT, irrespective of pCR \[[@b2-yujm-2019-00157],[@b10-yujm-2019-00157],[@b11-yujm-2019-00157],[@b21-yujm-2019-00157]\]. In these studies, Quah et al. \[[@b2-yujm-2019-00157]\] reported that "pathologic stage (ypTN stage)" was the most accurate predictor for DFS, while Gosens et al. \[[@b10-yujm-2019-00157]\] demonstrated that CRM positivity, lymph node status, and ypTNM stage were significantly associated with both local recurrence and overall survival on univariate analysis. In the latter study, CRM positivity was an independent predictor of local recurrence, but not of overall survival. In contrast, we determined that CRM positivity was an independent prognostic factor of both RFS and CSS, along with the ypTNM stage. Interestingly, a new staging system based on the combination of ypN stage and CRM status proposed by Gosens et al. was found to be a better prognostic tool than classic ypTNM staging in rectal cancer \[[@b11-yujm-2019-00157]\].

There is increasing evidence to suggest that CRM in rectal cancer is an important predictor of local recurrence, development of distant metastasis, and patient outcome \[[@b10-yujm-2019-00157],[@b21-yujm-2019-00157]-[@b25-yujm-2019-00157]\]. While many studies have used the standard definition of ≤1 mm as a CRM positivity \[[@b22-yujm-2019-00157],[@b26-yujm-2019-00157]\], others have reported that tumor cells within 2 mm from the margin were associated with an unfavorable prognosis \[[@b27-yujm-2019-00157],[@b28-yujm-2019-00157]\]. In this regard, by comparing cutoff values in rectal cancer patients who had received preoperative CRT, Hwang et al. \[[@b19-yujm-2019-00157]\] demonstrated that 1 mm was an appropriate measurement for determining CRM positivity. Furthermore, Park et al. \[[@b18-yujm-2019-00157]\] demonstrated that a 1 mm cutoff value could be used to discern CRM positivity used in the prognosis of patient outcome, in rectal cancer patients with and without preoperative CRT. In our study, CRM positivity was defined as ≤1 mm and was observed in 20.5%. Because our cohort was constructed solely from patients with residual disease, the percentage of CRM positivity was relatively high, although within the reported range of 4-21% \[[@b2-yujm-2019-00157],[@b10-yujm-2019-00157],[@b18-yujm-2019-00157],[@b19-yujm-2019-00157],[@b29-yujm-2019-00157]\]. Our data suggest that CRM status may be as powerful as ypTNM staging as a prognostic indicator for patient outcome in patients with residual rectal cancer after preoperative CRT. Although CRM status has known prognostic value, we noted that CRM data were occasionally absent from pathology reports and they could not be assessed from paraffin blocks owing to a lack of embedding all clinically relevant areas. In addition, owing to the fibrotic response to CRT, tumor depth could not be accurately determined on gross examination of the surgical specimen of some patients. Furthermore, it has also been reported that vital tumor cells can be found scattered throughout the whole fibrotic area, resulting in CRM positivity \[[@b10-yujm-2019-00157]\]. Thus, we recommend that in the case of preoperative CRT rectal cancers, CRM assessment should be considered for all tissue surrounding the entire tumor CRM, and be documented within the pathology report. In addition, the pathologists should not hesitate to determine CRM positivity and the clinicians should not be afraid it to decide accurate treatment strategies.

Interestingly in our study, TRG is associated with patient outcome but is not an independent prognostic factor in patients with residual rectal cancer after CRT. In addition, we observed only moderate reproducibility of TRG scoring between two pathologists, which was complicated by evaluating TRG solely in patients with residual tumor, also observed in a previous study \[[@b10-yujm-2019-00157]\]. This discrepancy highlights that using TRG to predict patient outcome in residual rectal cancer presents with some difficulty in practice.

We acknowledge that the data presented: (1) is a retrospective study from a single institution with a relatively homogeneous population; and (2) may have too few numbers in each patient subgroup to perform robust statistical analyses. Therefore, subsequent large-scale studies are needed to validate our results. Despite these limitations, this study is a comprehensive evaluation of clinicopathological prognostic factors associated with residual rectal cancer after preoperative CRT in an East Asian population.

In conclusion, CRM positivity was independent prognostic indicator that predicted for poorer patient outcome in relation to both RFS and CSS irrespective of ypTNM stage, in patients with residual rectal cancer who received preoperative CRT. Additionally, in these patients, CRM positivity retained significance as an independent prognostic indicator of poor outcome for RFS and CSS, irrespective of downstage or LNM. Finally, these results have implications for the stratification of patients at a higher risk of disease progression, and may help clinicians implement more effective treatment strategies in patients presenting with residual rectal cancer after CRT.
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###### 

Characteristics of the patients with residual rectal cancer after preoperative CRT (n=146)

  Characteristic                                                               *n*        \%
  ---------------------------------------------------------------------------- ---------- ------
  Age at diagnosis (yr)                                                                   
   Median                                                                      60         
   Range                                                                       29-85      
  Sex                                                                                     
   Male                                                                        102        69.9
   Female                                                                      44         30.1
  Tumor distance from anal verge (cm)                                                     
   \<5                                                                         112        76.7
   ≥5                                                                          34         23.3
  Residual tumor size (cm)                                                                
   Median                                                                      6.0        
   Range                                                                       2.3-10.0   
  Clinical T category                                                                     
   cT2                                                                         8          5.5
   cT3                                                                         121        82.9
   cT4                                                                         17         11.6
  Clinical N category                                                                     
   cN0                                                                         17         11.6
   cN1-3                                                                       129        88.4
  Preoperative CEA (ng/mL)^[a)](#tfn2-yujm-2019-00157){ref-type="table-fn"}^              
   ≤5                                                                          91         66.9
   \>5                                                                         45         33.1
  Tumor regression grade                                                                  
   0                                                                           4          2.7
   1                                                                           21         14.4
   2                                                                           55         37.7
   3                                                                           66         45.2
  Pathologic TNM stage                                                                    
   I                                                                           31         21.2
   II                                                                          68         46.6
   III                                                                         47         32.2
  Down-staged after CRT                                                                   
   No                                                                          54         37
   Yes                                                                         92         63
  *KRAS* mutation^[a)](#tfn2-yujm-2019-00157){ref-type="table-fn"}^                       
   Negative                                                                    76         72.4
   Positive                                                                    29         27.6
  *BRAF* mutation^[a)](#tfn2-yujm-2019-00157){ref-type="table-fn"}^                       
   Negative                                                                    101        96.2
   Positive                                                                    4          3.8

CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; TNM, tumor, node, metastasis.

Missing value is included.

###### 

Univariate analysis of prognostic factors in entire group with residual rectal cancer patients after preoperative CRT

  Clinicopathological characteristic                                           n (%)        Recurrence free survival   Cancer-specific survival                                            
  ---------------------------------------------------------------------------- ------------ -------------------------- -------------------------- ---------------- -------------- -------- --------------
  Age (yr)                                                                                                                                                                                 
   \<60                                                                        70 (47.9)    0.676                      0.897                      0.538-1.495      0.426          0.779    0.420-1.443
   ≥60                                                                         76 (52.1)                                                                                                   
  Sex                                                                                                                                                                                      
   Male                                                                        102 (69.9)   0.853                      1.053                      0.609-1.820      0.864          1.059    0.548-2.045
   Female                                                                      44 (30.1)                                                                                                   
  Pretreatment CEA^[b)](#tfn5-yujm-2019-00157){ref-type="table-fn"}^ (ng/mL)                                                                                                               
   \<5                                                                         91 (66.9)    0.580                      1.168                      0.674-2.023      0.217          1.502    0.784-2.879
   ≥5                                                                          45 (33.1)                                                                                                   
  Tumor distance from anal verge (cm)                                                                                                                                                      
   \<5                                                                         112 (76.7)   0.609                      1.170                      0.642-2.132      0.384          1.358    0.680-2.711
   ≥5                                                                          34 (23.3)                                                                                                   
  Residual tumor size (cm)                                                                                                                                                                 
   \<6.0                                                                       72 (49.3)    0.022                      1.830                      1.083-3.091      0.009          2.344    1.214-4.528
   ≥6.0                                                                        74 (50.7)                                                                                                   
  ypT category                                                                                                                                                                             
   T1                                                                          4 (2.7)                                                                                                     
   T2                                                                          33 (22.6)    \<0.001                    0.705                      0.085-5.856      \<0.001        0.357    0.037-3.431
   T3                                                                          100 (68.5)                              2.045                      0.281-14.870                    1.334    0.182-9.802
   T4                                                                          9 (6.2)                                 14.972                     1.843-121.603                   10.437   1.272-85.655
  ypN category                                                                                                                                                                             
   N0                                                                          99 (67.8)    \<0.001                                                                \<0.001                 
   N1                                                                          27 (18.5)    1.298                      0.656-2.569                0.291            1.049-5.005             
   N2                                                                          20 (13.7)    3.543                      1.918-6.546                6.262            3.076-12.746            
  Pathologic TNM stage                                                                                                                                                                     
   I                                                                           31 (21.2)    0.005                                                                  \<0.001                 
   II                                                                          68 (46.6)    2.327                      0.959-5.644                1.577            0.514-4.841             
   III                                                                         47 (32.2)    3.833                      1.575-9.326                5.04             1.747-14.541            
  Downstage                                                                                                                                                                                
   Yes                                                                         92 (63.0)    0.024                      0.558                      0.334-0.931      \<0.001        0.331    0.178-0.616
   No                                                                          54 (37.0)                                                                                                   
  Tumor regression grade                                                                                                                                                                   
   0                                                                           4 (2.7)      0.014                                                                  0.001                   
   1                                                                           21 (14.4)    0.308                      0.084-1.124                0.304            0.082-1.130             
   2                                                                           55 (37.7)    0.232                      0.069-0.774                0.179            0.052-0.619             
   3                                                                           66 (45.2)    0.173                      0.052-0.582                0.122            0.035-0.434             
  Lymphatic invasion                                                                                                                                                                       
   No                                                                          112 (76.7)   0.004                      2.161                      1.259-3.710      \<0.001        2.903    1.558-5.409
   Yes                                                                         34 (23.3)                                                                                                   
  Perineural invasion                                                                                                                                                                      
   No                                                                          112 (76.6)   \<0.001                    2.811                      1.656-.4.770     \<0.001        4.866    2.633-8.993
   Yes                                                                         34 (23.3)                                                                                                   
  Venous invasion                                                                                                                                                                          
   No                                                                          141 (96.6)   \<0.001                    40.488                     11.990-136.718   \<0.001        13.699   5.196-36.120
   Yes                                                                         5 (3.4)                                                                                                     
  Circumferential resection margin (mm)                                                                                                                                                    
   Positive (≤1)                                                               30 (20.5)    \<0.001                    3.563                      2.088-6.080      \<0.001        3.803    2.034-7.110
   Negative (\>1)                                                              116 (79.5)                                                                                                  
  *KRAS* mutation^[b)](#tfn5-yujm-2019-00157){ref-type="table-fn"}^                                                                                                                        
   Negative                                                                    76 (72.4)    0.107                      1.662                      0.890-3.104      0.122          1.776    0.849-3.718
   Positive                                                                    29 (27.6)                                                                                                   
  *BRAF* mutation^[b)](#tfn5-yujm-2019-00157){ref-type="table-fn"}^                                                                                                                        
   Negative                                                                    101 (96.2)   0.435                      1.747                      0.422-7.223      0.186          2.543    0.605-10.684
   Positive                                                                    4 (3.8)                                                                                                     

CEA, carcinoembryonic antigen; CRT, chemoradiotherapy; HR, hazard ratio; CI, confidence interval; TNM, tumor, node, metastasis.

*p*-values were calculated using log-rank test.

Missing value is included.

###### 

Univariate analysis of prognostic factors in subgrouping patients according to downstage and LNM after preoperative CRT

  Clinicopathological characteristic                                           Non-downstage group   Downstage group   non LNM group   LNM group                                                                       
  ---------------------------------------------------------------------------- --------------------- ----------------- --------------- ----------- ------- ------- ----------- --------- ------- ----------- --------- ---------
  Pretreatment CEA (ng/mL)^[b)](#tfn8-yujm-2019-00157){ref-type="table-fn"}^                                                                                                                                           
   \<5                                                                         30 (58.8)             0.659             0.646           61 (71.3)   0.282   0.095   67 (72.8)   0.346     0.092   24 (54.5)   0.541     0.454
   ≥5                                                                          21 (41.2)             24 (28.2)         25 (27.2)       20 (45.5)                                                                       
  Tumor distance from anal verge (cm)                                                                                                                                                                                  
   \<5                                                                         40 (74.1)             0.414             0.222           72 (78.3)   0.736   0.9     78 (78.8)   0.835     0.909   34 (72.3)   0.347     0.185
   ≥5                                                                          14 (25.9)             20 (21.7)         21 (21.2)       13 (27.7)                                                                       
  Residual tumor size (cm)                                                                                                                                                                                             
   \<6.0                                                                       23 (42.6)             0.451             0.354           49 (53.3)   0.024   0.008   52 (52.5)   0.018     0.009   20 (42.6)   0.566     0.331
   ≥6.0                                                                        31 (57.4)             43 (46.7)         47 (47.5)       27 (57.4)                                                                       
  ypT category                                                                                                                                                                                                         
   T1                                                                          0 (0)                 \<0.001           \<0.001         4 (4.3)     0.003   0.406   4 (4.0)     0.004     0.414   0 (0)       \<0.001   \<0.001
   T2                                                                          6 (11.1)              27 (29.3)         27 (27.3)       6 (12.8)                                                                        
   T3                                                                          41 (75.9)             59 (64.1)         66 (66.7)       34 (72.3)                                                                       
   T4                                                                          7 (10.0)              2 (2.2)           2 (2.0)         7 (14.9)                                                                        
  Tumor regression grade                                                                                                                                                                                               
   0                                                                           2 (3.7)               \<0.001           \<0.001         2 (2.2)     0.845   0.397   2 (2.0)     0.846     0.348   2 (4.3)     \<0.001   \<0.001
   1                                                                           8 (14.8)              13 (14.1)         13 (13.1)       8 (17.0)                                                                        
   2                                                                           22 (40.7)             33 (35.9)         26 (36.4)       19 (40.4)                                                                       
   3                                                                           22 (40.7)             44 (47.8)         48 (48.5)       18 (38.3)                                                                       
  Lymphatic invasion                                                                                                                                                                                                   
   No                                                                          25 (46.3)             0.041             0.035           87 (94.6)   0.924   0.287   94 (94.9)   0.964     0.301   18 (38.3)   0.12      0.144
   YES                                                                         29 (53.7)             5 (5.4)           5 (5.1)         29 (61.7)                                                                       
  Perineural invasion                                                                                                                                                                                                  
   No                                                                          32 (59.3)             \<0.001           \<0.001         80 (87.0)   0.286   0.105   86 (86.9)   0.409     0.136   26 (55.3)   \<0.001   \<0.001
   YES                                                                         22 (40.7)             12 (13.0)         13 (13.1)       21 (44.7)                                                                       
  Venous invasion                                                                                                                                                                                                      
   No                                                                          49 (90.7)             \<0.001           \<0.001         92 (100)    NE      NE      99 (100)    NE        NE      42 (89.4)   \<0.001   \<0.001
   YES                                                                         5 (9.3)               0 (0)             0 (0)           5 (10.6)                                                                        
  Circumferential resection margin (mm)                                                                                                                                                                                
   ≤1                                                                          44 (81.5)             \<0.001           \<0.001         72 (78.3)   0.002   0.002   78 (78.8)   \<0.001   0.001   38 (80.9)   \<0.001   \<0.001
   \>1                                                                         10 (18.5)             20 (21.7)         21 (21.2)       9 (19.1)                                                                        
  *KRAS* mutation^[b)](#tfn8-yujm-2019-00157){ref-type="table-fn"}^                                                                                                                                                    
   Negative                                                                    29 (69.0)             0.382             0.631           47 (74.6)   0.1     0.085   48 (71.6)   0.117     0.141   28 (73.7)   0.204     0.191
   Positive                                                                    13 (31.0)             16 (25.4)         19 (28.4)       10 (26.3)                                                                       
  *BRAF* mutation^[b)](#tfn8-yujm-2019-00157){ref-type="table-fn"}^                                                                                                                                                    
   Negative                                                                    39 (92.9)             0.223             0.204           62 (67.4)   0.483   0.672   66 (98.5)   0.491     0.681   35 (92.1)   0.277     0.278
   Positive                                                                    3 (7.1)               1 (1.1)           1 (1.5)         3 (7.9)                                                                         

LNM, lymph node metastasis; CEA, carcinoembryonic antigen; CRT, chemoradiotherapy; RFS, recurrence free survival; CSS, cancer-specific survival, NE, not evaluated.

*p*-values were calculated using log-rank test.

Missing value is included.

###### 

Multivariate analysis to determinate the independent prognostic factors in entire group with residual rectal cancer patients after preoperative CRT

  Variable                   Category                Recurrence free survival (multivariate analysis)   Cancer-specific survival (multivariate analysis)                                    
  -------------------------- ----------------------- -------------------------------------------------- -------------------------------------------------- -------------- --------- ------- -------------
  Pathologic TNM stage       III vs. I&II            0.105                                              1.744                                              0.890-3.418    0.004     3.413   1.484-7.851
  Residual tumor size (cm)   ≥6 vs. \<6              0.049                                              1.753                                              1.003-3.064    0.020     2.371   1.143-4.919
  Venous invasion            Present vs. absent      \<0.001                                            20.425                                             5.140-81.172   0.086     2.767   0.865-8.854
  Lymphatic invasion         Present vs. absent      0.889                                              1.050                                              0.528-2.089    0.875     0.939   0.427-2.063
  Perineural invasion        Present vs. absent      0.117                                              1.667                                              0.880-3.157    0.009     2.634   1.271-5.458
  CRM                        Positive vs. negative   \<0.001                                            3.613                                              2.034-6.418    \<0.001   4.133   2.027-8.426
  Tumor regression grade     0&1 vs. 2&3             0.425                                              1.311                                              0.673-2.555    0.368     1.404   0.670-2.941

CRT, chemoradiotherapy; HR, hazard ratio; CI, confidence interval; TNM, tumor, node, metastasis. vs., versus; CRM, circumferential resection margin.

[^1]: These authors contributed to this work as co-first authors
